Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis
The GRN policy improved the accessibility and affordability of PD-1 drugs. Health insurance policy-makers need to consider the legitimate interests of PD-1 drug manufacturers while ensuring the sustainability of the basic health insurance fund.
Authors
- Hongbin Yi (ORCID: https://orcid.org/0000-0003-2602-3959)
- Min-hong Cai
- Yingdan Cao (ORCID: https://orcid.org/0009-0006-7414-4674)
- Xiaoxia Wei (ORCID: https://orcid.org/0000-0003-2443-1203)
- Liping Kuai
- XU Dong-yan
- Sheng Han (ORCID: https://orcid.org/0000-0001-5975-3574)
- Yue Qiu (ORCID: https://orcid.org/0000-0003-4714-9745)
Institutions
- Fujian Medical University (CN)
- Peking University (CN)
- Chinese Pharmaceutical Association (CN)
- Peking University International Hospital (CN)
- Fujian Provincial Hospital (CN)
- Beijing Hua Xin Hospital (CN)
Publication Details
- Journal
- Journal of Global Health
- Published
- 2025-04-18
- DOI
- https://doi.org/10.7189/jogh.15.04069
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26